<code id='1762DC5F3F'></code><style id='1762DC5F3F'></style>

<acronym id='1762DC5F3F'></acronym>

<center id='1762DC5F3F'><center id='1762DC5F3F'><tfoot id='1762DC5F3F'></tfoot></center><abbr id='1762DC5F3F'><dir id='1762DC5F3F'><tfoot id='1762DC5F3F'></tfoot><noframes id='1762DC5F3F'>

<optgroup id='1762DC5F3F'><strike id='1762DC5F3F'><sup id='1762DC5F3F'></sup></strike><code id='1762DC5F3F'></code></optgroup>

<b id='1762DC5F3F'><label id='1762DC5F3F'><select id='1762DC5F3F'><dt id='1762DC5F3F'><span id='1762DC5F3F'></span></dt></select></label></b><u id='1762DC5F3F'></u>

~~<i id='1762DC5F3F'><strike id='1762DC5F3F'><tt id='1762DC5F3F'><pre id='1762DC5F3F'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

knowledge

author：fashion 2025-09-30 04:15:01 Page View：77321

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

advertisement

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Primary care doctor shortage won't be solved by free med school tuition
Next article： Peter Hotez and the public health issue of online harassment

focus

Activists slam private health insurers over coverage restrictions

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Study: New antibiotic targets gonorrhea as well as last existing drug

Study: New antibiotic targets gonorrhea as well as last existing drug

ColorizedscanningelectronmicrographofNeisseriagonorrhoeaebacteria,whichcausesgonorrhea.NIAIDAnimport

Peter Hotez and the public health issue of online harassment

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Class action alleges UnitedHealth concealed DOJ probe

AdobeYou’rereadingthewebversionofHealthCareInc.,STAT’sweeklynewsletterfollowingtheflowofmoneyinmedic

read more